全文获取类型
收费全文 | 3804篇 |
免费 | 815篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 98篇 |
儿科学 | 125篇 |
妇产科学 | 110篇 |
基础医学 | 143篇 |
口腔科学 | 17篇 |
临床医学 | 1131篇 |
内科学 | 985篇 |
皮肤病学 | 149篇 |
神经病学 | 271篇 |
特种医学 | 108篇 |
外科学 | 800篇 |
综合类 | 26篇 |
预防医学 | 148篇 |
眼科学 | 107篇 |
药学 | 78篇 |
中国医学 | 1篇 |
肿瘤学 | 341篇 |
出版年
2024年 | 16篇 |
2023年 | 142篇 |
2022年 | 47篇 |
2021年 | 136篇 |
2020年 | 214篇 |
2019年 | 89篇 |
2018年 | 256篇 |
2017年 | 176篇 |
2016年 | 211篇 |
2015年 | 189篇 |
2014年 | 299篇 |
2013年 | 328篇 |
2012年 | 155篇 |
2011年 | 137篇 |
2010年 | 237篇 |
2009年 | 289篇 |
2008年 | 165篇 |
2007年 | 136篇 |
2006年 | 147篇 |
2005年 | 137篇 |
2004年 | 108篇 |
2003年 | 103篇 |
2002年 | 89篇 |
2001年 | 89篇 |
2000年 | 91篇 |
1999年 | 71篇 |
1998年 | 59篇 |
1997年 | 69篇 |
1996年 | 60篇 |
1995年 | 53篇 |
1994年 | 26篇 |
1993年 | 20篇 |
1992年 | 27篇 |
1991年 | 32篇 |
1990年 | 27篇 |
1989年 | 19篇 |
1988年 | 19篇 |
1987年 | 13篇 |
1986年 | 25篇 |
1985年 | 21篇 |
1984年 | 17篇 |
1983年 | 7篇 |
1979年 | 5篇 |
1978年 | 9篇 |
1975年 | 6篇 |
1972年 | 4篇 |
1967年 | 5篇 |
1955年 | 6篇 |
1954年 | 4篇 |
1949年 | 6篇 |
排序方式: 共有4638条查询结果,搜索用时 109 毫秒
1.
Jamaal L. Benjamin MD PhD Rebecca Dennis DO Stacy White Jr MD David Munson MD Sudha A. Anupindi MD Maciej Piskunowicz MD Kassa Darge MD PhD Ami Gokli MD Misun Hwang MD 《Journal of ultrasound in medicine》2020,39(5):1031-1036
Bowel diseases of prematurity, including necrotizing enterocolitis, are dreaded ailments of neonates. Early diagnosis is difficult, with clinical and radiographic findings often inconclusive. We present a novel use of contrast-enhanced ultrasound in detection of pediatric bowel disease. Early identification of compromised blood flow or an at-risk bowel can be quantitatively detected and monitored. This ability has implications for guidance of emerging therapies, allowing targeting of inflammation. These findings represent an advancement in detection of bowel disease in neonates. 相似文献
2.
3.
4.
5.
6.
Darren R. Feldman MD Yasser Ged MBBS Chung-Han Lee PhD Andrea Knezevic MS Ana M. Molina MD Ying-Bei Chen PhD Joshua Chaim DO Devyn T. Coskey MS Samuel Murray MS Satish K. Tickoo MD Victor E. Reuter MD Sujata Patil PhD Han Xiao MD Jahan Aghalar MD Arlyn J. Apollo MD Maria I. Carlo MD Robert J. Motzer MD Martin H. Voss MD 《Cancer》2020,126(24):5247-5255
7.
Fibromyalgia is a syndrome of widespread pain, nonrestorative sleep, disturbed mood, and fatigue. Optimal treatment involves
a multidisciplinary approach with a team of health care providers using pharmacologic and nonpharmacologic treatment. Because
of the heterogeneity of the illness, management should be individualized for the patient. Pharmacologic treatment should address
issues of pain control, sleep disturbance, fatigue, and any underlying coexisting mood disorder. Nonpharmacologic treatment
should include patient education, a regular exercise and stretching program, and cognitive behavioral therapy. All of these
are essential to improving functional capacity and quality of life. This review provides general guidelines in initiating
a successful pharmacologic treatment program for patients with fibromyalgia. 相似文献
8.
C. M. Crceles J. M. Serrano P. Marín E. Escudero E. Fernndez‐Varn 《Transboundary and Emerging Diseases》2006,53(6):300-304
The pharmacokinetics (PK) of moxifloxacin in healthy white New Zealand rabbits was studied following intravenous (IV) and subcutaneous (SC) administration routes as well as a SC long‐acting poloxamer 407 gel formulation (SC‐P407). Moxifloxacin concentrations were determined by high‐performance liquid chromatography assay with fluorescence detection. Mean half‐life for IV, SC and SC‐P407 routes was 2.15, 5.41 and 11.09 h. Clearance value after IV dosing was 0.78 l/kg/h. After SC administration, the mean absolute bioavailability was 117% and the Cmax was 1.61 ± 0.49 mg/l. After SC‐P407 administration, the bioavailability was 44% and the Cmax 1.83 was ±0.62 mg/l. No adverse effects were observed in any of the rabbits following IV, SC and SC‐P407 administration of moxifloxacin. Minimal inhibitory concentrations of moxifloxacin against different strains of Staphylococcus aureus from different european countries were used to compute the main pharmacodynamic (PD) surrogate markers of efficacy. The high tolerability of this SC‐P407 formulation and the favourable PK behaviour such as the long half‐life, acceptable bioavailability and excellent PK–PD ratios achieved indicate that it is likely to be effective in rabbits. 相似文献
9.
10.